

Invicro Appoints Hidenori Seshimo as Vice President of Biomarker Services, Japan

30 August 2019 | News

Seshimo brings to Invicro over 20 years of experience in drug discovery, pharmaceutical imaging and central clinical laboratories



Invicro , a member of the Konica Minolta Group and a leading provider of biomarkers for imaging, core lab services and software for research and development of drugs, announced today the appointment of Hidenori Seshimo as Vice President of Biomarker Services, Japan.

Seshimo brings to Invicro over 20 years of experience in drug discovery, pharmaceutical imaging and central clinical laboratories. With a focus on the Asia-Pacific region and other emerging markets, Dr. Seshimo will expand Invicro's capabilities in clinical imaging and its advanced pathology imaging solutions, including quantitative immunohistochemistry services, through at Quanticell , Konica Minolta's innovative technology using integrated phosphorus points.

"We are absolutely delighted that Seshimo is now part of the Invicro team," said Dr. Jack Hoppin, co-founder and CEO of Invicro. "As Intellico strengthens its capabilities in core clinical labs and imaging capabilities for CROs globally, Dr. Seshimo will be instrumental in collaborating with our global sponsors in the pharmacy and biotechnologies to provide them with imaging biomarkers, advanced analytics and the best services for central laboratories in the industry in all therapeutic areas."

Most recently, Seshimo was Managing Director of Bioclinica Japan KK and Regional Vice President of Business Development at Bioclinica, Japan, where he established and developed his medical imaging business for the Central Laboratories. Prior to Bioclinica, Seshimo was the lead account executive at Covance, where he explored the Japanese clinical laboratory market and learned to respond to and accommodate the needs of local customers.

"It's really exciting to be part of a forward-thinking team like Invicro," said Seshimo. "Invicro is a global industry leader in imaging biomarker services and central laboratories; I look forward to expanding these capabilities, which will add value to the clinical research projects of our clients around the world."

Seshimo holds a Bachelor's degree in Engineering, a Master's degree in Engineering and completed a PhD course, all focused on synthetic and biological chemistry, from Kyoto University, Japan. Seshimo obtained five patents for compounds developed while at Eisai, and has also published extensively for his research.